These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23543607)

  • 21. Influence of polymers on the bioavailability of microencapsulated celecoxib.
    Homar M; Ubrich N; El Ghazouani F; Kristl J; Kerc J; Maincent P
    J Microencapsul; 2007 Nov; 24(7):621-33. PubMed ID: 17763056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Promising dissolution enhancement effect of soluplus on crystallized celecoxib obtained through antisolvent precipitation and high pressure homogenization techniques.
    Homayouni A; Sadeghi F; Varshosaz J; Afrasiabi Garekani H; Nokhodchi A
    Colloids Surf B Biointerfaces; 2014 Oct; 122():591-600. PubMed ID: 25124835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of drug-excipient interaction in the formulation of celecoxib tablets.
    Bozdağ-Pehlivan S; Subaşi B; Vural I; Unlü N; Capan Y
    Acta Pol Pharm; 2011; 68(3):423-33. PubMed ID: 21648198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel three-dimensional large-pore mesoporous carbon matrix as a potential nanovehicle for the fast release of the poorly water-soluble drug, celecoxib.
    Zhang Y; Wang H; Li C; Sun B; Wang Y; Wang S; Gao C
    Pharm Res; 2014 Apr; 31(4):1059-70. PubMed ID: 24287624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced dissolution of megestrol acetate microcrystals prepared by antisolvent precipitation process using hydrophilic additives.
    Cho E; Cho W; Cha KH; Park J; Kim MS; Kim JS; Park HJ; Hwang SJ
    Int J Pharm; 2010 Aug; 396(1-2):91-8. PubMed ID: 20558265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of crystal size on the in vitro dissolution and oral absorption of nitrendipine in rats.
    Xia D; Cui F; Piao H; Cun D; Piao H; Jiang Y; Ouyang M; Quan P
    Pharm Res; 2010 Sep; 27(9):1965-76. PubMed ID: 20585842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mesoporous carbon with spherical pores as a carrier for celecoxib with needle-like crystallinity: improve dissolution rate and bioavailability.
    Zhu W; Zhao Q; Sun C; Zhang Z; Jiang T; Sun J; Li Y; Wang S
    Mater Sci Eng C Mater Biol Appl; 2014 Jun; 39():13-20. PubMed ID: 24863191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Celecoxib Crystallized from Hydrophilic Polymeric Solutions Showed Modified Crystalline Behavior with an Improved Dissolution Profile.
    Sahoo RN; Satapathy BS; Ray J; Dash R; Mallick S
    Assay Drug Dev Technol; 2021; 19(4):237-245. PubMed ID: 33970022
    [No Abstract]   [Full Text] [Related]  

  • 29. Modeling of corneal and retinal pharmacokinetics after periocular drug administration.
    Amrite AC; Edelhauser HF; Kompella UB
    Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):320-32. PubMed ID: 18172109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modification of microenvironmental pH of nanoparticles for enhanced solubility and oral bioavailability of poorly water-soluble celecoxib.
    Ran Woo M; Bak YW; Cheon S; Suk Kim J; Hun Ji S; Park S; Woo S; Oh Kim J; Giu Jin S; Choi HG
    Int J Pharm; 2024 Jun; 659():124179. PubMed ID: 38692498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of a biphasic test for characterization of in vitro drug release of immediate release formulations of celecoxib and its relevance to in vivo absorption.
    Shi Y; Gao P; Gong Y; Ping H
    Mol Pharm; 2010 Oct; 7(5):1458-65. PubMed ID: 20704265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of spray-drying to enhance celecoxib solubility.
    Fouad EA; El-Badry M; Mahrous GM; Alanazi FK; Neau SH; Alsarra IA
    Drug Dev Ind Pharm; 2011 Dec; 37(12):1463-72. PubMed ID: 21707230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced dissolution of celecoxib by supersaturating self-emulsifying drug delivery system (S-SEDDS) formulation.
    Song WH; Park JH; Yeom DW; Ahn BK; Lee KM; Lee SG; Woo HS; Choi YW
    Arch Pharm Res; 2013 Jan; 36(1):69-78. PubMed ID: 23325487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three levels face centered central composite design of colon targeted micro-particulates system of celecoxib: screening of formulations variables and in vivo studies.
    Nandy BC; Verma V; Dey S; Mazumder B
    Curr Drug Deliv; 2014; 11(5):621-35. PubMed ID: 24844925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Silica-lipid hybrid (SLH) versus non-lipid formulations for optimising the dose-dependent oral absorption of celecoxib.
    Tan A; Davey AK; Prestidge CA
    Pharm Res; 2011 Sep; 28(9):2273-87. PubMed ID: 21560021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ursolic Acid Nanocrystals for Dissolution Rate and Bioavailability Enhancement: Influence of Different Particle Size.
    Pi J; Liu Z; Wang H; Gu X; Wang S; Zhang B; Luan H; Zhu Z
    Curr Drug Deliv; 2016; 13(8):1358-1366. PubMed ID: 26953239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preparation of polylactide-co-glycolide nanoparticles incorporating celecoxib and their antitumor activity against brain tumor cells.
    Kim TH; Jeong YI; Jin SG; Pei J; Jung TY; Moon KS; Kim IY; Kang SS; Jung S
    Int J Nanomedicine; 2011; 6():2621-31. PubMed ID: 22114493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preparation of microspheres containing low solubility drug compound by electrohydrodynamic spraying.
    Bohr A; Kristensen J; Stride E; Dyas M; Edirisinghe M
    Int J Pharm; 2011 Jun; 412(1-2):59-67. PubMed ID: 21511018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physicochemical and pharmacokinetic characterization of amorphous solid dispersion of tranilast with enhanced solubility in gastric fluid and improved oral bioavailability.
    Onoue S; Kojo Y; Aoki Y; Kawabata Y; Yamauchi Y; Yamada S
    Drug Metab Pharmacokinet; 2012; 27(4):379-87. PubMed ID: 22240843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of calcined Mg-Al-hydrotalcite to enhance the stability of celecoxib in the amorphous form.
    Ambrogi V; Perioli L; Marmottini F; Rossi C
    Eur J Pharm Biopharm; 2007 May; 66(2):253-9. PubMed ID: 17123798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.